{"transactions":[{"id":1016812,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":155262,"price":17.75,"value":2755900.5,"ownership":{"direct":false,"nature":"By Pontifax Late Stage Fund, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to the Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 and Tomer Kariv and Ran Nussbaum may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of his or its pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016811,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":1226412,"price":17.75,"value":21768813.0,"ownership":{"direct":false,"nature":"By Pontifax (China) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016810,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":1121045,"price":17.75,"value":19898548.75,"ownership":{"direct":false,"nature":"By Pontifax (Cayman) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Cayman IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1016809,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74168,"kind":"person","name":"Kariv Tomer","position":7,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":40939,"kind":"person","name":"Nussbaum Ran","position":8,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2025-10-17T21:53:28.000Z","date":"2025-10-15","kind":"sale","planned":false,"acquired":false,"shares":2284612,"price":17.75,"value":40551863.0,"ownership":{"direct":false,"nature":"By Pontifax (Israel) IV, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by Israel IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000921895-25-002765","document":"form414601002_10172025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000092189525002765/form414601002_10172025.xml","form_type":"4"}},{"id":1039382,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T20:15:07.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":10000000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":411681},"source":{"system":"sec-edgar","filing":"0001726334-25-000003","document":"form4-09162025_040904.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000172633425000003/form4-09162025_040904.xml","form_type":"4"}},{"id":1039381,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:15:07.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":15,"value":15000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":1411681,"source":{"system":"sec-edgar","filing":"0001726334-25-000003","document":"form4-09162025_040904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000172633425000003/form4-09162025_040904.xml","form_type":"4"}},{"id":1039380,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T20:15:07.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":411681,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities."}],"balance_after":411681,"source":{"system":"sec-edgar","filing":"0001726334-25-000003","document":"form4-09162025_040904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000172633425000003/form4-09162025_040904.xml","form_type":"4"}},{"id":2101542,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T21:42:36.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1914,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by China IV. Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":1914},"source":{"system":"sec-edgar","filing":"0001209191-22-059053","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919122059053/doc4.xml","form_type":"4"}},{"id":2101541,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T21:42:36.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1723,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":1723},"source":{"system":"sec-edgar","filing":"0001209191-22-059053","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919122059053/doc4.xml","form_type":"4"}},{"id":2101540,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Options (obligation to sell)","published_at":"2022-11-30T21:42:36.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":3539,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested and exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2023-10-07","underlying":"Common Stock","underlying_shares":3539},"source":{"system":"sec-edgar","filing":"0001209191-22-059053","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919122059053/doc4.xml","form_type":"4"}},{"id":2101539,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T21:42:36.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1914,"price":0.0001,"value":0.1914,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by China IV. Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1226412,"source":{"system":"sec-edgar","filing":"0001209191-22-059053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919122059053/doc4.xml","form_type":"4"}},{"id":2101538,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T21:42:36.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":1723,"price":0.0001,"value":0.1723,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Cayman IV. Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1121045,"source":{"system":"sec-edgar","filing":"0001209191-22-059053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919122059053/doc4.xml","form_type":"4"}},{"id":2101537,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-30T21:42:36.000Z","date":"2022-11-29","kind":"other","acquired":false,"shares":3539,"price":0.0001,"value":0.3539,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an exercise of a call option (obligation to sell), pursuant to a stock option agreement dated January 21, 2016, by and between the Pontifax (Israel) IV, L.P. (\"Israel IV\"), Pontifax (Cayman) IV, L.P. (\"Cayman IV\") and Pontifax (China) IV, L.P. (\"China IV\") and a certain securityholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Israel IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2284612,"source":{"system":"sec-edgar","filing":"0001209191-22-059053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919122059053/doc4.xml","form_type":"4"}},{"id":2710686,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":592592,"price":1.35,"value":799999.2,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\"), the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Each of Management 4, Pontifax IV, Late Stage Fund and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":616592,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2710685,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1422222,"price":1.35,"value":1919999.7,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1989551,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2710684,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":2630487,"price":1.35,"value":3551157.45,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":3679797,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2710683,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1280624,"price":1.35,"value":1728842.4,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1791470,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2973275,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T21:38:21.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":6000,"price":50,"value":300000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":155262,"source":{"system":"sec-edgar","filing":"0001209191-20-059404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120059404/doc4.xml","form_type":"4"}},{"id":2973274,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T21:38:21.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":14400,"price":50,"value":720000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1228326,"source":{"system":"sec-edgar","filing":"0001209191-20-059404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120059404/doc4.xml","form_type":"4"}},{"id":2973273,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T21:38:21.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":12966,"price":50,"value":648300.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1122768,"source":{"system":"sec-edgar","filing":"0001209191-20-059404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120059404/doc4.xml","form_type":"4"}},{"id":2973272,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T21:38:21.000Z","date":"2020-11-17","kind":"purchase","acquired":true,"shares":26634,"price":50,"value":1331700.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2288151,"source":{"system":"sec-edgar","filing":"0001209191-20-059404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120059404/doc4.xml","form_type":"4"}},{"id":3137703,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":2,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":5,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148998,"kind":"organization","name":"Pontifax Management III G.P. (2011) Ltd.","position":6,"cik":"0001726335","reported_name":"Pontifax Management III G.P. (2011) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148999,"kind":"organization","name":"Pontifax Management Fund III L.P.","position":7,"cik":"0001726340","reported_name":"Pontifax Management Fund III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149000,"kind":"organization","name":"Pontifax (Cayman) III, L.P.","position":8,"cik":"0001726028","reported_name":"Pontifax (Cayman) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149001,"kind":"organization","name":"Pontifax (Israel) III, L.P.","position":9,"cik":"0001726038","reported_name":"Pontifax (Israel) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T20:10:59.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":3.39,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-20-001306","document":"form4-05222020_040544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920001306/form4-05222020_040544.xml","form_type":"4"}},{"id":3137702,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":2,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":5,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148998,"kind":"organization","name":"Pontifax Management III G.P. (2011) Ltd.","position":6,"cik":"0001726335","reported_name":"Pontifax Management III G.P. (2011) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148999,"kind":"organization","name":"Pontifax Management Fund III L.P.","position":7,"cik":"0001726340","reported_name":"Pontifax Management Fund III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149000,"kind":"organization","name":"Pontifax (Cayman) III, L.P.","position":8,"cik":"0001726028","reported_name":"Pontifax (Cayman) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149001,"kind":"organization","name":"Pontifax (Israel) III, L.P.","position":9,"cik":"0001726038","reported_name":"Pontifax (Israel) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-22T20:10:59.000Z","date":"2020-05-20","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, \"Pontifax\").\n\nPontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P.\n\nPontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P.\n\nMr. Kariv will assign the economic interests of the reported securities to Pontifax; and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":3.39,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-20-001306","document":"form4-05222020_040544.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920001306/form4-05222020_040544.xml","form_type":"4"}},{"id":3178032,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":36858,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36858},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178031,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":79653,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":79653},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178030,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":88460,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":88460},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178029,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":163612,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":163612},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178028,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":68654,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":68654},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178027,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":91538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":91538},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178026,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":82425,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":82425},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178025,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":169307,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":169307},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178024,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":737226,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737226},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178023,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":663825,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":663825},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178022,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":1363542,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1363542},"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178021,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":43750,"price":16,"value":700000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":149262,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178020,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":105000,"price":16,"value":1680000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1213926,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178019,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":94546,"price":16,"value":1512736.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1109802,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178018,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":194203,"price":16,"value":3107248.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2261517,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178017,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":36858,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":105512,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178016,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":79653,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1108926,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178015,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":88460,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1015256,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178014,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":163612,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":2067314,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178013,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":68654,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The securities are held by Pontifax Late Stage Fund, L.P. (\"Late Stage\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. Pursuant to Strategic Alliance Agreement, dated August 9, 2018, between Late Stage, Israel IV, Cayman IV and China IV (collectively the, \"Pontifax IV Funds\"), Late Stage invests side-by-side with the Pontifax IV Funds. By virtue of the strategic relationship, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Late Stage in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax IV Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Management 4 and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":68654,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178012,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":91538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1029273,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178011,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":82425,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":926796,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178010,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":169307,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1903702,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178009,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":737226,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Pontifax (China) IV, L.P. (\"China IV\"). Management 4 is the ultimate general partner of China IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":937735,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178008,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":663825,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Pontifax (Cayman) IV, L.P. (\"Cayman IV\"). Management 4 is the ultimate general partner of Cayman IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":844371,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3178007,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":2,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":5,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":6,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T21:18:02.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":1363542,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the ultimate general partner of Israel IV. As a result Management 4 may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Management 4 disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1734395,"source":{"system":"sec-edgar","filing":"0001209191-20-024231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000120919120024231/doc4.xml","form_type":"4"}},{"id":3373051,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153848,"kind":"organization","name":"Pontifax (Israel) V, L.P.","position":2,"cik":"0001792890","reported_name":"Pontifax (Israel) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153849,"kind":"organization","name":"Pontifax (Cayman) V, L.P.","position":3,"cik":"0001792893","reported_name":"Pontifax (Cayman) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153850,"kind":"organization","name":"Pontifax (China) V, L.P.","position":4,"cik":"0001792891","reported_name":"Pontifax (China) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153851,"kind":"organization","name":"Pontifax 5 G.P. L.P.","position":5,"cik":"0001792892","reported_name":"Pontifax 5 G.P. L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":6,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":7,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":8,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-11-14T00:10:44.000Z","date":"2019-11-13","kind":"exercise","acquired":false,"shares":5500001,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Includes (a) 534,342 shares held by Pontifax (Israel) V, L.P., (b) 142,726 shares held by Pontifax (Cayman) V, L.P. and (c) 207,603 shares held by Pontifax (China) V, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pontifax 5 G.P. L.P. (\"Pontifax 5 GP\") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax Management\") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":884671},"source":{"system":"sec-edgar","filing":"0000899243-19-027228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000089924319027228/doc4.xml","form_type":"4"}},{"id":3373050,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153848,"kind":"organization","name":"Pontifax (Israel) V, L.P.","position":2,"cik":"0001792890","reported_name":"Pontifax (Israel) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153849,"kind":"organization","name":"Pontifax (Cayman) V, L.P.","position":3,"cik":"0001792893","reported_name":"Pontifax (Cayman) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153850,"kind":"organization","name":"Pontifax (China) V, L.P.","position":4,"cik":"0001792891","reported_name":"Pontifax (China) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153851,"kind":"organization","name":"Pontifax 5 G.P. L.P.","position":5,"cik":"0001792892","reported_name":"Pontifax 5 G.P. L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":6,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":7,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":8,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-14T00:10:44.000Z","date":"2019-11-13","kind":"exercise","acquired":true,"shares":884671,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-6.217 basis immediately prior the closing of the Issuer's initial public offering on November 13, 2019 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Includes (a) 668,732 shares held by Pontifax (Israel) V, L.P., (b) 178,623 shares held by Pontifax (Cayman) V, L.P., (c) 259,816 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pontifax 5 G.P. L.P. (\"Pontifax 5 GP\") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax Management\") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":1134671,"source":{"system":"sec-edgar","filing":"0000899243-19-027228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000089924319027228/doc4.xml","form_type":"4"}},{"id":3373049,"issuer":{"id":73682,"kind":"organization","name":"89bio, Inc.","symbol":"ETNB"},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153848,"kind":"organization","name":"Pontifax (Israel) V, L.P.","position":2,"cik":"0001792890","reported_name":"Pontifax (Israel) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153849,"kind":"organization","name":"Pontifax (Cayman) V, L.P.","position":3,"cik":"0001792893","reported_name":"Pontifax (Cayman) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153850,"kind":"organization","name":"Pontifax (China) V, L.P.","position":4,"cik":"0001792891","reported_name":"Pontifax (China) V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":153851,"kind":"organization","name":"Pontifax 5 G.P. L.P.","position":5,"cik":"0001792892","reported_name":"Pontifax 5 G.P. L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":6,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74167,"kind":"organization","name":"Pontifax Late Stage GP Ltd.","position":7,"cik":"0001793770","reported_name":"Pontifax Late Stage GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74166,"kind":"organization","name":"Pontifax Late Stage Fund L.P.","position":8,"cik":"0001793769","reported_name":"Pontifax Late Stage Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-14T00:10:44.000Z","date":"2019-11-11","kind":"purchase","acquired":true,"shares":250000,"price":16,"value":4000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 11, 2019, Pontifax (Israel) V, L.P. purchased 134,390 shares of the Issuer's common stock, Pontifax (Cayman) V, L.P. purchased 35,897 shares of the Issuer's common stock, Pontifax (China) V, L.P. (collectively, the \"Pontifax Entities\") purchased 52,213 shares of the Issuer's common stock and Pontifax Late Stage Fund L.P. (\"Late Stage L.P.\") purchased 27,500 shares of the Issuer's common stock at a price of $16.00 per share in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Includes (a) 134,390 shares held by Pontifax (Israel) V, L.P., (b) 35,897 shares held by Pontifax (Cayman) V, L.P., (c) 52,213 shares held by Pontifax (China) V, L.P. and (d) 27,500 shares held by Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pontifax 5 G.P. L.P. (\"Pontifax 5 GP\") is the general partner of each of the Pontifax Entities, and Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax Management\") is the general partner of Pontifax 5 GP. Mr. Tomer Kariv is one of two Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Mr. Kariv disclaims beneficial ownership of those shares held by the Pontifax Entities, except to the extent of his pecuniary interest therein. Late Stage L.P. invests side by side with Pontifax 5 GP pursuant to a Strategic Alliance Agreement with Pontifax 5 GP. Pontifax Late Stage GP Ltd. (\"Late Stage GP\") is the general partner of Late Stage L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from footnote 6) and the sole shareholder of Late Stage GP is Mr. Shlomo Karako. By virtue of the strategic relationship, each of Pontifax 5 GP, Pontifax Management, Ran Nussbaum, and Tomer Kariv may be deemed to share voting and dispositive power with respect to the shares held by Late Stage L.P. in a manner similar to the voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr. Kariv disclaims beneficial ownership of such shares, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0000899243-19-027228","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1726334/000089924319027228/doc4.xml","form_type":"4"}},{"id":3478187,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:44:05.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":24000,"price":9,"value":216000.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\"), the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Each of Management 4, Pontifax IV, Late Stage Fund and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001144204-19-032482","document":"tv524335_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032482/tv524335_form4.xml","form_type":"4"}},{"id":3478186,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:44:05.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":46933,"price":9,"value":422397.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":567329,"source":{"system":"sec-edgar","filing":"0001144204-19-032482","document":"tv524335_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032482/tv524335_form4.xml","form_type":"4"}},{"id":3478185,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:44:05.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":86806,"price":9,"value":781254.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1049310,"source":{"system":"sec-edgar","filing":"0001144204-19-032482","document":"tv524335_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032482/tv524335_form4.xml","form_type":"4"}},{"id":3478184,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T20:44:05.000Z","date":"2019-06-24","kind":"purchase","acquired":true,"shares":42261,"price":9,"value":380349.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":510846,"source":{"system":"sec-edgar","filing":"0001144204-19-032482","document":"tv524335_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420419032482/tv524335_form4.xml","form_type":"4"}},{"id":3509085,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":2,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":5,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148998,"kind":"organization","name":"Pontifax Management III G.P. (2011) Ltd.","position":6,"cik":"0001726335","reported_name":"Pontifax Management III G.P. (2011) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148999,"kind":"organization","name":"Pontifax Management Fund III L.P.","position":7,"cik":"0001726340","reported_name":"Pontifax Management Fund III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149000,"kind":"organization","name":"Pontifax (Cayman) III, L.P.","position":8,"cik":"0001726028","reported_name":"Pontifax (Cayman) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149001,"kind":"organization","name":"Pontifax (Israel) III, L.P.","position":9,"cik":"0001726038","reported_name":"Pontifax (Israel) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-29T21:15:22.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":9.02,"expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-19-000624","document":"form4-05292019_020508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588919000624/form4-05292019_020508.xml","form_type":"4"}},{"id":3509084,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":2,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":4,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":5,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148998,"kind":"organization","name":"Pontifax Management III G.P. (2011) Ltd.","position":6,"cik":"0001726335","reported_name":"Pontifax Management III G.P. (2011) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":148999,"kind":"organization","name":"Pontifax Management Fund III L.P.","position":7,"cik":"0001726340","reported_name":"Pontifax Management Fund III L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149000,"kind":"organization","name":"Pontifax (Cayman) III, L.P.","position":8,"cik":"0001726028","reported_name":"Pontifax (Cayman) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149001,"kind":"organization","name":"Pontifax (Israel) III, L.P.","position":9,"cik":"0001726038","reported_name":"Pontifax (Israel) III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-29T21:15:22.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, \"Pontifax\").\n\nPontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P.\n\nPontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P.\n\nMr. Kariv will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":20000,"derivative":{"exercise_price":9.02,"expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-19-000624","document":"form4-05292019_020508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588919000624/form4-05292019_020508.xml","form_type":"4"}},{"id":3889181,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":2,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":3,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T22:19:46.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by Ran Nussbaum, a general partner of Pontifax 4.  Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax 4 and it may be deemed the indirect beneficial owner of the security. Pontifax 4 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":40000,"derivative":{"exercise_price":23.27,"expiration_date":"2028-06-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-038660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118038660/doc4.xml","form_type":"4"}},{"id":3889180,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":2,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":3,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T22:19:46.000Z","date":"2018-06-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by Tomer Kariv, a general partner of Pontifax Management 4 G.P. (2015) Ltd. (\"Pontifax 4\").  Mr. Kariv will assign the economic interests of the reported securities to Pontifax 4 and it may be deemed the indirect beneficial owner of the security. Pontifax 4 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein."}],"balance_after":40000,"derivative":{"exercise_price":23.27,"expiration_date":"2028-06-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-18-038660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118038660/doc4.xml","form_type":"4"}},{"id":3952308,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:37:26.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":93333,"price":9.75,"value":909996.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":520396,"source":{"system":"sec-edgar","filing":"0001209191-18-027114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027114/doc4.xml","form_type":"4"}},{"id":3952307,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:37:26.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":172626,"price":9.75,"value":1683103.5,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":962504,"source":{"system":"sec-edgar","filing":"0001209191-18-027114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027114/doc4.xml","form_type":"4"}},{"id":3952306,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-01T20:37:26.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":84041,"price":9.75,"value":819399.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the follow-on offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on April 30, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":468585,"source":{"system":"sec-edgar","filing":"0001209191-18-027114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118027114/doc4.xml","form_type":"4"}},{"id":3984105,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":1600,"price":8,"value":12800.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":427063,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984104,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":2959,"price":8,"value":23672.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":789878,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984103,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-22","kind":"purchase","acquired":true,"shares":1441,"price":8,"value":11528.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":384544,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984102,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":1760,"price":7.55,"value":13288.0,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":425463,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984101,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":3255,"price":7.55,"value":24575.25,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":786919,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}},{"id":3984100,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-03-23T20:16:48.000Z","date":"2018-03-21","kind":"purchase","acquired":true,"shares":1585,"price":7.55,"value":11966.75,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. (\"Cayman IV\"). Pontifax IV GP L.P. (\"Pontifax IV\") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. (\"Management 4\") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":383103,"source":{"system":"sec-edgar","filing":"0001209191-18-021389","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021389/doc4.xml","form_type":"4"}}]}